Early detection is critical to advancing how we treat neurodegenerative diseases. By the time symptoms appear, significant neuronal damage has already occurred.
Relying on symptoms alone limits early trial enrollment and has slowed therapeutic development. That’s why Resonant partners with biopharma—to explore blood-based biomarkers that may support earlier detection, monitoring, and intervention.
Current diagnostics for neurodegenerative diseases remain limited in breadth and accessibility. These limitations stem from the fact that clinical diagnoses often occur too late to mitigate neuron loss, protein-based assays may not reliably match disease progression, and other procedures—such as spinal taps and advanced imaging—can be invasive or geographically inaccessible.
Neurodegenerative conditions are defined by neuron loss. Our early research suggests that blood-based biomarkers that reflect cell-specific markers of neurodegeneration may be detectable years before clinical symptoms appear. These panels are in development to support researchers with objective tools for studying neurodegeneration and exploring earlier, more targeted interventions.
We are actively exploring partnerships with biopharma to evaluate our platform as a companion tool in the development of treatments for neurodegenerative diseases.
Our technology aims to support therapeutic development and patient care through:
Interested in learning more about our ongoing work and how it could support your research and development?
